Pharmacologic class (EPC) · 2 drug pages

GLP-2 analog: adverse event reports filed with FDA

13,300 reports list a drug in this class as a suspect or interacting product, 2009–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

13,300
reports across the class: 0.1% of all reports; 1,065
reports, 12 months to June 2026: 1,184 in the 12 months before; 84.1%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

GLP-2 analog is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 13,300 adverse event reports received by FDA, 0.1% of the database, from October 2009 to June 2026.

1,065 reports arrived in the 12 months to June 2026, down 10% from 1,184 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 84.1% of the class's reports are marked serious, 8.6% record death among the outcomes and 60% record hospitalisation, as reported.

Across the class the reactions recorded most often are weight decreased (9.5%), vascular device infection (8.8%) and nausea (8.3%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Teduglutide	generic	9,271	961	94.4%	Vascular device infection
GattexTeduglutide	brand	4,029	104	60.3%	Nausea

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Weight decreasedweight loss9.5%1,257
Vascular device infection8.8%1,174
Nauseafeeling sick8.3%1,099
Product dose omission issuea dose was missed8%1,065
Abdominal painstomach or belly pain8%1,060
Diarrhoealoose or frequent stools7.9%1,054
Weight increasedweight gain6.6%873
Dehydrationdehydration6.5%867
Vomitingbeing sick6.4%845
Deaththe patient died; cause not stated by this term5.8%774
Abdominal distensiona bloated abdomen5.4%722
Pyrexiafever4.7%625
Hospitalisationadmission to hospital4.4%585
Inappropriate schedule of product administrationthe product was taken at the wrong times4.1%541
Decreased appetitereduced appetite4%527
Sepsisa severe body-wide response to infection3.9%519
Device related infectionan infection related to the device3.8%509
Abdominal pain upperupper stomach pain3.7%490
Product use issuea problem in how the product was used3.6%484
Fatiguetiredness3.4%455
Pneumonialung infection3.3%443
Intestinal obstructiona blocked bowel3.1%413
Drug ineffectivethe medicine did not work as expected3.1%410
Malaisegeneral feeling of being unwell3.1%408
Flatulencewind3%401

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death8.6%1,149

Life-threatening1.8%241

Hospitalisation (initial or prolonged)60%7,976

Disability0.9%117

Congenital anomaly0.1%7

Other serious62.4%8,305

Not serious15.9%2,121

Patient age

Under 21%138

2 to 117.3%966

12 to 171.7%228

18 to 449.1%1,210

45 to 6423.4%3,116

65 to 7412.6%1,675

75 and over6%803

Age not given38.8%5,164

Who reported

Physician14.7%1,949

Pharmacist2.6%352

Other health professional38.4%5,111

Lawyer0%0

Consumer or non-health professional42.9%5,705

Not given1.4%183

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about GLP-2 analog reports

Which drugs are in the GLP-2 analog class on this site?

Teduglutide and Gattex. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

13,300 reports through June 2026, 1,065 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

weight decreased (9.5%), vascular device infection (8.8%), nausea (8.3%), product dose omission issue (8%) and abdominal pain (8%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.